MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

Monitor complete blood cell counts prior to initiation ... to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved ...

Multiple THIO trials planned in additional cancer indications ... for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look ...

Cell aging has always been an important topic in biological research, and telomere shortening is one of the key issues in ...

The interplay between aging and cellular senescence reveals insights into chronic inflammation and potential strategies for ...

Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") and certain officers.  The class action, filed in the United States District ...

A faculty member at University of Indiana Bloomington for 47 years, Ostrom died of pancreatic cancer in 2012 ... the ends of chromosomes as cells divide (Blackburn has likened them to shoelace caps).